Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis

Patients with cystic fibrosis (CF) frequently experience pulmonary exacerbations that may lead to a faster subsequent decline in pulmonary function; however, this relationship has not been clearly established. The purpose of this study was to determine the association between the frequency of pulmonary exacerbations and subsequent forced expiratory volume in 1 sec (FEV1) decline in adults and children with CF.

[1]  M. Bugiani,et al.  Recurrent exacerbations affect FEV(1) decline in adult patients with cystic fibrosis. , 2009, Respiratory medicine.

[2]  M. Kosorok,et al.  Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. , 2005, JAMA.

[3]  T. Liou,et al.  Predictive 5-year survivorship model of cystic fibrosis. , 2001, American journal of epidemiology.

[4]  Michael R Knowles,et al.  Genetic modifiers of lung disease in cystic fibrosis. , 2005, The New England journal of medicine.

[5]  J L Hankinson,et al.  Spirometric reference values from a sample of the general U.S. population. , 1999, American journal of respiratory and critical care medicine.

[6]  T. Koepsell,et al.  Epidemiologic Methods: Studying the Occurrence of Illness , 2003 .

[7]  R. Hornung,et al.  Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. , 2002, Chest.

[8]  C. Merlo,et al.  Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. , 2008, American journal of respiratory and critical care medicine.

[9]  M. Rosenfeld,et al.  Cystic fibrosis pulmonary exacerbations. , 2006, The Journal of pediatrics.

[10]  C. Goss,et al.  Effect of ambient air pollution on pulmonary exacerbations and lung function in cystic fibrosis. , 2004, American journal of respiratory and critical care medicine.

[11]  C. Goss,et al.  Exacerbations in cystic fibrosis · 1: Epidemiology and pathogenesis , 2007, Thorax.

[12]  S. Fitzsimmons.  The changing epidemiology of cystic fibrosis. , 1994, Current problems in pediatrics.

[13]  Charles A. Johnson,et al.  Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. , 2007, The Journal of pediatrics.

[14]  T. Lieu,et al.  The Cost of Medical Care for Patients With Cystic Fibrosis in a Health Maintenance Organization , 1999, Pediatrics.

[15]  M. Kosorok,et al.  Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition , 2001, Pediatric pulmonology.

[16]  Margaret Rosenfeld,et al.  Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. , 2010, American journal of respiratory and critical care medicine.

[17]  D. Sanders,et al.  Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis , 2010, Pediatric pulmonology.

[18]  R. Henry,et al.  Defining an exacerbation of pulmonary disease in cystic fibrosis * , 2001, Pediatric pulmonology.

[19]  David Wypij,et al.  Pulmonary function between 6 and 18 years of age , 1993, Pediatric pulmonology.

[20]  W. Warwick,et al.  Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. , 2000, American journal of respiratory and critical care medicine.

[21]  J. Emerson,et al.  Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis , 2002, Pediatric pulmonology.

[22]  M. Corey,et al.  Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. , 1997, The Journal of pediatrics.

[23]  P. Burgel,et al.  One-year outcome after severe pulmonary exacerbation in adults with cystic fibrosis. , 2005, American journal of respiratory and critical care medicine.

[24]  K. Wilson,et al.  Lung function decline in cystic fibrosis patients and timing for lung transplantation referral. , 2004, Chest.

[25]  A F Roche,et al.  CDC growth charts: United States. , 2000, Advance data.

[26]  B. Ramsey,et al.  Management of pulmonary disease in patients with cystic fibrosis. , 1996, The New England journal of medicine.

[27]  M. Whiteford,et al.  Outcome of Burkholderia (Pseudomonas) cepacia colonisation in children with cystic fibrosis following a hospital outbreak. , 1995, Thorax.

[28]  P. Margolis,et al.  The association of socioeconomic status with outcomes in cystic fibrosis patients in the United States. , 2001, American journal of respiratory and critical care medicine.

[29]  C. Goss,et al.  Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis. , 2005, Chest.

[30]  S. Willsie.  Lung Function Decline in Cystic Fibrosis Patients and Timing for Lung Transplantation ReferralRosenbluth DB, Wilson K, Ferkol T, et al (Washington Univ, St Louis) Chest 126:412-419, 2004§ , 2006 .

[31]  P. J. Byard,et al.  Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. , 1995, Journal of clinical epidemiology.